drugset
drugset / Trial / NCT06492330

Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM

NCT06492330 ↗

Completed 62 enrolled Shanghai Jiao Tong University School of Medicine
RandomizedParallel-groupDouble-blindTreatment

Summary

This is an exploratory study evaluating CS0159 in combination with Semaglutide in MASH patients with obesity and T2DM.

Timeline

Start
2024-07-19
Primary completion
2025-02-28
Completion
2025-04-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator CS0159 Unknown 4 mg Oral

Indications

metabolic dysfunction-associated steatohepatitis obesity disorder type 2 diabetes mellitus